Reply To: Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
DOI: 10.1016/s0140-6736(16)31324-1Author: Eugene R Bleecker et al.Published: 2016-10

Forum › Forums › Make a Request › DOI › Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial

DOI: 10.1016/s0140-6736(16)31324-1Author: Eugene R Bleecker et al.Published: 2016-10
› Reply To: Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
DOI: 10.1016/s0140-6736(16)31324-1Author: Eugene R Bleecker et al.Published: 2016-10

April 15, 2026 at 7:34 am #1169
marvinasciiMarvin ASCII
Participant

Title: Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
Journal: The Lancet
Source url: https://doi.org/10.1016/s0140-6736(16)31324-1